Marijuana Retail Report

August 31, 2020

On Tuesday, July 21, the Food and Drug Administration (“FDA”) released draft guidance for clinical research related to the development and manufacturing of cannabis-based drugs, which gained particular interest following the legalization of hemp in December 2018.

Although the guidance does not cover other FDA-regulated products, such as hemp-derived CBD (“Hemp CBD”)-infused foods and dietary supplements, the last section of the document – Section III C. – addresses delta-9 THC and dosage calculations that may be indicative of the manner in which the FDA may propose to regulate hemp-derived finished products.